Adenylyl cyclases as innovative therapeutic goals.
Pharmacological modulation of intracellular cyclic AMP (cAMP) signalling could provide new therapeutic and experimental tools. Although drugs interfering with this pathway have traditionally targeted membrane receptors, the effector enzyme adenylyl cyclase (AC), which functions as a signalling catalyst, also presents an interesting target. Thus, development of isoform-selective stimulator and/or inhibitor compounds for AC could lead to organ-specific pharmacotherapeutics for treating heart failure, cancer and neurodegenerative diseases. In this review, the potential of AC as the object of drug therapy is discussed.
Pavan
Barbara
B
Department of Biology and Evolution, General Physiology Section, University of Ferrara, Ferrara, Italy. pvnbbr@unife.it
Biondi
Carla
C
Dalpiaz
Alessandro
A
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D015195:Drug Design; D004789:Enzyme Activation; D020536:Enzyme Activators / Q000737:chemistry / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes; D015394:Molecular Structure; D018696:Neuroprotective Agents / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D013329:Structure-Activity Relationship
D000067956:Adenylyl Cyclase Inhibitors; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D018696:Neuroprotective Agents; D000242:Cyclic AMP; D000262:Adenylyl Cyclases